Add to ORKGAgarwal R, Filippatos G, Pitt B, et al. Cardiovascular and kidney outcomes with finerenone in patients with type 2 diabetes and chronic kidney disease: the FIDELITY pooled analysis. Eur Heart J. 2022;43:474-84. ttps://pubmed.ncbi.nlm.nih.gov/3502354
International audienceAimsFinerenone significantly reduced the risk of kidney and cardiovascular (CV...
Aims This prespecified analysis of the FIDELIO-DKD trial compared the effects of finerenone, a sele...
Aims Finerenone significantly reduced the risk of kidney and cardiovascular (CV) outcomes in patien...
Background Patients with stage 4 chronic kidney disease (CKD) and type 2 diabetes have limited treat...
Background: The FIDELIO-DKD trial evaluated the effect of the nonsteroidal, selective mineralocortic...
Background: In patients with type 2 diabetes (T2D), risks of cardiovascular mortality and heart fail...
OBJECTIVE: Finerenone reduced the risk of kidney and cardiovascular events in people with chronic ki...
BACKGROUND: Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has favorabl...
Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) have a residual risk of CKD pro...
OBJECTIVE Finerenone significantly improved cardiorenal outcomes in patients with chronic kidney dis...
Background: Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced alb...
Background: Chronic kidney disease and type 2 diabetes are independently associated with heart failu...
Background: Chronic kidney disease is frequently associated with hypertension and poorly controlled ...
Background: In FIGARO-DKD, finerenone reduced the risk of cardiovascular events in patients with typ...
IMPORTANCE: It is currently unclear whether chronic kidney disease (CKD)-associated cardiovascular r...
International audienceAimsFinerenone significantly reduced the risk of kidney and cardiovascular (CV...
Aims This prespecified analysis of the FIDELIO-DKD trial compared the effects of finerenone, a sele...
Aims Finerenone significantly reduced the risk of kidney and cardiovascular (CV) outcomes in patien...
Background Patients with stage 4 chronic kidney disease (CKD) and type 2 diabetes have limited treat...
Background: The FIDELIO-DKD trial evaluated the effect of the nonsteroidal, selective mineralocortic...
Background: In patients with type 2 diabetes (T2D), risks of cardiovascular mortality and heart fail...
OBJECTIVE: Finerenone reduced the risk of kidney and cardiovascular events in people with chronic ki...
BACKGROUND: Finerenone, a selective nonsteroidal mineralocorticoid receptor antagonist, has favorabl...
Patients with chronic kidney disease (CKD) and type 2 diabetes (T2D) have a residual risk of CKD pro...
OBJECTIVE Finerenone significantly improved cardiorenal outcomes in patients with chronic kidney dis...
Background: Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced alb...
Background: Chronic kidney disease and type 2 diabetes are independently associated with heart failu...
Background: Chronic kidney disease is frequently associated with hypertension and poorly controlled ...
Background: In FIGARO-DKD, finerenone reduced the risk of cardiovascular events in patients with typ...
IMPORTANCE: It is currently unclear whether chronic kidney disease (CKD)-associated cardiovascular r...
International audienceAimsFinerenone significantly reduced the risk of kidney and cardiovascular (CV...
Aims This prespecified analysis of the FIDELIO-DKD trial compared the effects of finerenone, a sele...
Aims Finerenone significantly reduced the risk of kidney and cardiovascular (CV) outcomes in patien...